Drug Trial Radar · NCT07226895
A Study Exploring Changes in a Variety of Biomarkers Following Dosing With MT1988 in Participants at Clinical High Risk for Psychosis
Last checked: Nov 19, 2026Latest source record: Jun 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
150
Planned (sponsor's estimate)
Start
Mar 3, 2026
Primary completion
Sep 2027
Study completion Oct 2027
Sponsor
- Lead sponsor
- Monument Therapeutics LimitedIndustry
- Sponsor type
- Industry
- Collaborators
- National Institute of Mental Health (NIMH); Foundation for the National Institutes of Health; Accelerating Medicines Partnership (AMP)
- First posted
- Nov 12, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Basic science
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 17 years, up to 30 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to learn how tests undertaken by people at high risk of developing psychosis (aged 17 to 30 years old) change when those people are given the study drug MT1988 daily for 8 weeks. This will help identify tests that could be used in later trials developing treatments for symptoms in people at high risk of developing psychosis, to measure whether those new treatments are effective. The main question this trial aims to answer is: Can any of the tests (biomarkers) used in this study detect changes in participants dosed with one of two different dose levels of MT1988? Researchers will compare the results from two dose levels of MT1988 to a placebo group. Researchers do not expect to see the test results change in participants taking placebo and this will be compared to changes expected in test results in participants taking MT1988. Participants will: * take a dose of MT1988 or placebo twice per day for 8 weeks * attend clinic appointments every two weeks to undertake assessments * report any side effects they experience to the researchers
Conditions
- Clinical High Risk for Psychosis (CHR)
Interventions
MT1988 Low DoseDrug
Oral dosing MT1988; dose level 1
MT1988 High DoseDrug
Oral dosing MT1988; dose level 2
PlaceboDrug
Oral Placebo; blinded to match MT1988 all doses
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline to week 8 in test of verbal memory (List Learning Task) as measured by the Penn Computerized Neurobehavioral Battery (PennCNB) test batteryTime frame: Day 56
- Change from baseline to week 8 in attenuated positive symptoms as measured by PSYCHS-CT total scoreTime frame: Day 56
- Change from baseline to week 8 in negative symptoms as measured by the Negative Symptom Inventory - Psychosis Risk (NSI-PR) total scoreTime frame: Day 56
Locations
15 sites in 1 country. Site status is shown where the registry gives one.
University of California, Irvine
Irvine, California · Recruiting
University of California
Los Angeles, California · Recruiting
University of California, San Francisco
San Francisco, California · Recruiting
Yale University Conneticut Mental Health Center
New Haven, Connecticut · Recruiting
Beth Israel Deaconess Medical Center
Boston, Massachusetts · Recruiting
Washington University
St Louis, Missouri · Recruiting
Northwell Health
Glen Oaks, New York · Recruiting
Columbia University
New York, New York · Recruiting
Icahan School of Medicine at Mount Sinai
New York, New York · Recruiting
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina · Recruiting
Ohio State University
Columbus, Ohio · Recruiting
Prevention Science Institute
Eugene, Oregon · Recruiting
University of Pennsylvania
Philadelphia, Pennsylvania · Recruiting
Temple University
Philadelphia, Pennsylvania · Recruiting
University of Pittsburgh School of Medicine
Pittsburgh, Pennsylvania · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.